D. Thibeault

发表

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

Steven R. LaPlante, P. Bonneau, D. Lamarre, 2003, Nature.

Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2-P3 sites.

P. Anderson, B. Thavonekham, B. Simoneau, 1998, Bioorganic & medicinal chemistry.

2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors.

L. Tong, S. Pav, D. Lamarre, 2000, Journal of medicinal chemistry.

Molecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of Resistance

G. Kukolj, P. White, Jeff O'meara, 2012, The Journal of Biological Chemistry.

In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335

G. Kukolj, M. Massariol, P. White, 2011, Antimicrobial Agents and Chemotherapy.

Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy.

P. Anderson, C. Chabot, B. Thavonekham, 1999, Bioorganic & medicinal chemistry.

Enzymatic characterization of purified recombinant human renin.

D. Lamarre, G. McKercher, L. Pilote, 1995, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Improved purification protocol of the HSV-1 protease catalytic domain, using immunoaffinity.

P. Bonneau, M. Massariol, G. McKercher, 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Peptide-based inhibitors of the hepatitis C virus serine protease.

D. Lamarre, S. LaPlante, M. Poirier, 1998, Bioorganic & medicinal chemistry letters.

Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061

D. Lamarre, P. White, D. Thibeault, 2004, Journal of Virology.

Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.

M. Massariol, P. White, M. Marquis, 2010, Biochemical and biophysical research communications.

Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.

M. Massariol, E. Welchner, P. White, 2009, Biochemistry.

The human renin infused rat: use as an in vivo model for the biological evaluation of human renin inhibitors.

D. Lamarre, P. Anderson, L. Pilote, 1999, Canadian Journal of Physiology and Pharmacology.

An NS3 Serine Protease Inhibitor Abrogates Replication of Subgenomic Hepatitis C Virus RNA*

D. Lamarre, A. Pause, G. Kukolj, 2003, Journal of Biological Chemistry.

In Vitro Characterization of a Purified NS2/3 Protease Variant of Hepatitis C Virus*

D. Lamarre, A. Pause, L. Pilote, 2001, The Journal of Biological Chemistry.

Human Rhinovirus VPg Uridylylation AlphaScreen for High-Throughput Screening

P. White, D. Thibeault, C. Fenwick, 2014, Journal of biomolecular screening.

An NS 3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

P. Bonneau, D. Lamarre, P. Anderson, 2003 .

Solution Structure of Substrate-based Ligands When Bound to Hepatitis C Virus NS3 Protease Domain*

D. Lamarre, S. LaPlante, G. Kukolj, 1999, The Journal of Biological Chemistry.

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

Peter W. White, J. Duan, M. Garneau, 2010, Antimicrobial Agents and Chemotherapy.

An NS 3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

P. Bonneau, D. Lamarre, P. Anderson, 2003 .

Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease

D. Lamarre, C. Yoakim, P. Anderson, 1997, Antimicrobial agents and chemotherapy.

Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position.

Martin Poirier, D. Lamarre, M. Poirier, 2004, Journal of medicinal chemistry.

Rapid, sensitive and efficient HPLC assays for HIV-1 proteinase.

M. Emmanuel, D. Thibeault, R. Betageri, 1993, Journal of biochemical and biophysical methods.

Bound Structure and Biochemical Mechanism of Action of BI 201335, a Potent, Non-covalent Inhibitor of HCV NS3-NS4A Protease

O. Hucke, P. White, D. Thibeault, 2010 .

758 CHARACTERIZATION OF RESISTANT MUTANTS SELECTED IN VITRO BY THE HCV NS3/4A PROTEASE INHIBITOR BI 201335

G. Kukolj, M. Massariol, P. White, 2010 .

777 PRECLINICAL CHARACTERIZATION OF NON-COVALENT HCV NS3/4A PROTEASE INHIBITOR BI 201335

J. Duan, M. Garneau, G. Kukolj, 2010 .

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

D. Lamarre, L. Doyon, L. Pilote, 1996, Journal of virology.

Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

D. Lamarre, L. Doyon, G. McKercher, 1997, Journal of virology.

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

D. Lamarre, J. Rancourt, M. Bailey, 1998, Bioorganic & medicinal chemistry letters.

Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335*

O. Hucke, P. White, N. Goudreau, 2011, The Journal of Biological Chemistry.

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

D. Lamarre, J. Rancourt, M. Bailey, 2000, Bioorganic & medicinal chemistry letters.

Tissue Specificity of Endothelin Binding Sites

D. Thibeault, G. Bolger, F. Liard, 1990, Journal of Cardiovascular Pharmacology.

Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.

L. Tong, S. Pav, D. Lamarre, 1997, Journal of medicinal chemistry.